Company news
Immatics N.v. (NASDAQ:IMTX) news
Immatics N.v. news releases on 6ix. Latest, Aug 25, 2026: Immatics Announces $150 Million Underwritten Offering
Press releases & updates
Immatics Announces $150 Million Underwritten Offering
August 25, 2026
Immatics N : Announces Second Quarter 2026 Financial Results and Business Update
August 18, 2026
Immatics Announces Second Quarter 2026 Financial Results and Business Update
August 18, 2026
Immunomic Therapeutics Announces First Patient Dosed in Phase 1 Trial of Cancer Vaccine Candidate ITI-5000
July 20, 2026
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
July 17, 2026
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
May 31, 2026
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
May 31, 2026
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
May 29, 2026
Immatics Announces First Quarter 2026 Financial Results and Business Update
May 12, 2026
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
April 20, 2026
PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
April 17, 2026
Immatics Announces Full Year 2025 Financial Results and Business Update
March 4, 2026
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
December 11, 2025
Immatics Announces $125 Million Underwritten Offering
December 5, 2025
Immatics Announces Third Quarter 2025 Financial Results and Business Update
November 17, 2025
Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps
November 12, 2025
Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps
November 11, 2025
Immatics Appoints Amie Krause as Chief People Officer
October 27, 2025
Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium
October 19, 2025
Immatics Appoints Venkat Ramanan as Chief Financial Officer
October 1, 2025
Immatics Announces Second Quarter 2025 Financial Results and Business Update
August 13, 2025
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
May 31, 2025
Immatics Announces First Quarter 2025 Financial Results and Business Update
May 13, 2025
Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting
April 23, 2025
Immatics Announces Full Year 2024 Financial Results and Business Update
March 27, 2025
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
November 17, 2024
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
November 7, 2024
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
October 9, 2024
Immatics Announces Proposed $150 Million Public Offering
October 9, 2024
Immatics Announces Pricing of $150 Million Public Offering
October 9, 2024
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
October 3, 2024
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
September 15, 2024
Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024
September 5, 2024
Immatics Announces Second Quarter 2024 Financial Results and Business Update
August 12, 2024
Immatics Appoints Alise Reicin to Board of Directors
July 30, 2024
Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024
July 17, 2024
Immatics Announces First Quarter 2024 Financial Results and Business Update
May 13, 2024
Immatics Announces Full Year 2023 Financial Results and Corporate Update
March 20, 2024
Immatics Announces Proposed Public Offering
January 16, 2024
Immatics Announces Pricing of $175 Million Public Offering
January 16, 2024
Immatics Announces Third Quarter 2023 Financial Results and Business Update
November 13, 2023
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
November 7, 2023
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
October 23, 2023
Immatics Announces Second Quarter 2023 Financial Results and Business Update
August 16, 2023
Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
August 9, 2023
Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
July 23, 2023
Immatics Announces First Quarter 2023 Financial Results and Business Update
May 15, 2023
Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME
May 1, 2023
Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration
April 30, 2023
Immatics Announces Full Year 2022 Financial Results and Corporate Update
March 20, 2023